SCHEMBL17405283

SCHEMBL17405283

Cc1nc2ccccc2n1-c1ccccc1-n1c2ccccc2c2c3c4ccccc4oc3c3c(c4ccccc4n3-c3ccccc3)c21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.49
HTT P42858 1/20 0.49
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.42
LMNA P02545 3/20 0.42
ALDH1A1 P00352 4/20 0.37
L3MBTL1 Q9Y468 2/20 0.36
HSD17B10 Q99714 3/20 0.36
POLB P06746 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HPGD P15428 1/20 0.36
DUSP3 P51452 1/20 0.36
PTPN5 P54829 1/20 0.36
PTPN11 Q06124 1/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
CA12 O43570 1/20 0.35
CA9 Q16790 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17405285 0.94 MAPK1 (0.54) MAPK1HTTTSHRSMN1; SMN2LMNA
SCHEMBL17405249 0.91 MAPK1 (0.51) MAPK1HTTTSHRSMN1; SMN2LMNA
SCHEMBL17405294 0.89 ALDH1A1 (0.44) MAPK1HTTSMN1; SMN2LMNAALDH1A1
SCHEMBL17405293 0.89 ESR1 (0.43) MAPK1HTTSMN1; SMN2LMNAALDH1A1
SCHEMBL17405308 0.87 RECQL (0.43) MAPK1HTTTSHRSMN1; SMN2LMNA
SCHEMBL17405304 0.86 RAB9A (0.41) MAPK1HTTSMN1; SMN2LMNAALDH1A1
SCHEMBL17405276 0.84 ALDH1A1 (0.45) MAPK1HTTSMN1; SMN2LMNAALDH1A1
SCHEMBL17405282 0.84 ESR1 (0.47) MAPK1HTTSMN1; SMN2LMNAALDH1A1
SCHEMBL17405297 0.84 ESR1 (0.50) MAPK1HTTSMN1; SMN2LMNAALDH1A1
SCHEMBL17405263 0.84 NPC1 (0.41) MAPK1HTTTSHRSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9887367-B2 Heterocyclic compound, material for organic electroluminescent elements using same, organic electroluminescent element using same, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2018-02-06 US disclosed
US-9887367-B2 Heterocyclic compound, material for organic electroluminescent elements using same, organic electroluminescent element using same, and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2018-02-06 US disclosed
US-20160005977-A1 HETEROCYCLIC COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME, ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2016-01-07 US disclosed
US-20160005977-A1 HETEROCYCLIC COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME, ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160005977-A1 HETEROCYCLIC COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS USING SAME, ORGANIC ELECTROLUMINESCENT ELEMENT USING SAME, AND ELECTRONIC DEVICE ODC1, NOTUM, OR10J3 MAPK1 3181/4885HTT 2182/4885TSHR 4480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.